$ASNS
ACTELIS NETWORKS INC Stock $asns

$asns Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000121390024069173 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$2.541M	$3.431M	$1.017M
YoY Change	200.71%	80.96%	-59.87%
Cost Of Revenue	$798.0K	$1.488M	$663.0K
YoY Change	28.92%	17.72%	-54.68%
Gross Profit	$1.743M	$1.943M	$354.0K
YoY Change	671.24%	207.44%	-66.95%
Gross Profit Margin	68.6%	56.63%	34.81%
Selling, General & Admin	$1.517M	$1.437M	$1.424M
YoY Change	-8.72%	-14.52%	-39.61%
% of Gross Profit	87.03%	73.96%	402.26%
Research & Development	$543.0K	$603.0K	$585.0K
YoY Change	-21.42%	-9.87%	-18.41%
% of Gross Profit	31.15%	31.03%	165.25%
Depreciation & Amortization	$3.000K	$4.000K	$7.000K
YoY Change	-70.0%	-33.33%	-216.67%
% of Gross Profit	0.17%	0.21%	1.98%
Operating Expenses	$2.060M	$1.877M	$2.009M
YoY Change	-12.45%	-20.13%	-34.67%
Operating Profit	-$317.0K	$66.00K	-$1.655M
YoY Change	-85.1%	-103.84%	-17.42%
Interest Expense	-$194.0K	-$144.0K	-$276.0K
YoY Change	-220.5%	-184.21%	-42.26%
% of Operating Profit		-218.18%
Other Income/Expense, Net
YoY Change
Pretax Income	-$511.0K	-$78.00K	-$1.931M
YoY Change	-41.26%	-95.1%	-22.2%
Income Tax
% Of Pretax Income
Net Earnings	-$511.0K	-$78.00K	-$1.931M
YoY Change	-41.06%	-95.1%	-22.2%
Net Earnings / Revenue	-20.11%	-2.27%	-189.87%
Basic Earnings Per Share	-$0.09	-$0.01
Diluted Earnings Per Share	-$0.09	-$0.01	-$0.67
COMMON SHARES
Basic Shares Outstanding	6.016M shares	3.354M shares	2.716M shares
Diluted Shares Outstanding	6.015M shares	4.258M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.241M	$2.412M	$817.0K
YoY Change	138.4%	-28.68%	-85.32%
Cash & Equivalents	$2.241M	$2.412M	$620.0K
Short-Term Investments	$0.00	$0.00	$197.0K
Other Short-Term Assets	$781.0K	$1.281M	$1.905M
YoY Change	-27.01%	38.64%	68.73%
Inventory	$2.372M	$2.158M	$2.526M
Prepaid Expenses			$198.0K
Receivables	$1.828M	$690.0K	$664.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$7.222M	$6.541M	$5.912M
YoY Change	33.37%	-16.92%	-45.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$52.00K	$55.00K	$61.00K
YoY Change	-21.21%	-21.43%	-23.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.476M	$1.761M	$5.250M
YoY Change	-74.01%	-68.73%	37.0%
Total Long-Term Assets	$1.528M	$1.816M	$5.311M
YoY Change	-73.39%	-68.15%	35.76%
TOTAL ASSETS
Total Short-Term Assets	$7.222M	$6.541M	$5.912M
Total Long-Term Assets	$1.528M	$1.816M	$5.311M
Total Assets	$8.750M	$8.357M	$11.22M
YoY Change	-21.58%	-38.43%	-24.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$893.0K	$1.421M	$1.769M
YoY Change	-59.22%	-25.91%	-0.67%
Accrued Expenses	$2.218M	$2.557M	$2.682M
YoY Change	6.63%	11.08%	125.38%
Deferred Revenue	$277.0K	$206.0K	$389.0K
YoY Change
Short-Term Debt	$927.0K	$1.045M	$0.00
YoY Change
Long-Term Debt Due		$460.0K	$1.335M
YoY Change		-62.39%	141.41%
Total Short-Term Liabilities	$5.075M	$6.471M	$6.912M
YoY Change	-23.47%	-3.65%	11.45%
LONG-TERM LIABILITIES
Long-Term Debt	$150.0K	$263.0K	$3.154M
YoY Change	-95.28%	-92.39%	-31.81%
Other Long-Term Liabilities	$16.00K	$27.00K	$769.0K
YoY Change	-36.0%	-15.63%	5.78%
Total Long-Term Liabilities	$614.0K	$749.0K	$3.923M
YoY Change	-82.87%	-86.3%	-26.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.075M	$6.471M	$6.912M
Total Long-Term Liabilities	$614.0K	$749.0K	$3.923M
Total Liabilities	$5.689M	$7.220M	$10.84M
YoY Change	-44.31%	-40.75%	-6.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$42.26M	-$41.75M	-$39.69M
YoY Change	11.93%	13.18%	18.82%
Common Stock	$1.000K	$1.000K	$39.92M
YoY Change	-100.0%	0.0%	3991600.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.833M	$936.0K	$388.0K
YoY Change
Total Liabilities & Shareholders Equity	$8.750M	$8.357M	$11.22M
YoY Change	-21.58%	-38.43%	-24.27%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$511.0K	-$78.00K	-$1.931M
YoY Change	-41.06%	-95.1%	-22.2%
Depreciation, Depletion And Amortization	$3.000K	$4.000K	$7.000K
YoY Change	-70.0%	-33.33%	-216.67%
Cash From Operating Activities	-$2.438M	-$2.140M	-$1.387M
YoY Change	8.36%	73.42%	-30.37%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$1.000K
YoY Change	-100.0%		-97.06%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$198.0K	$2.390M
YoY Change	-100.0%	-80.42%	-160.26%
Cash From Investing Activities	$0.00	$198.0K	$2.391M
YoY Change	-100.0%	-80.42%	-160.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.621M	167.0K	1.171M
YoY Change	-953.16%	-94.47%	-257.82%
NET CHANGE
Cash From Operating Activities	-2.438M	-2.140M	-1.387M
Cash From Investing Activities	0.000	198.0K	2.391M
Cash From Financing Activities	1.621M	167.0K	1.171M
Net Change In Cash	-817.0K	-1.775M	2.175M
YoY Change	-51.66%	-163.42%	-132.63%
FREE CASH FLOW
Cash From Operating Activities	-$2.438M	-$2.140M	-$1.387M
Capital Expenditures	$0.00	$0.00	-$1.000K
Free Cash Flow	-$2.438M	-$2.140M	-$1.386M
YoY Change	7.88%	73.42%	-29.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2033747	shares
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.72
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2333381	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4000994	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41375
	dei	Entity Registrant Name EntityRegistrantName	ACTELIS NETWORKS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	52-2160309
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4039 Clipper Court
	dei	Entity Address City Or Town EntityAddressCityOrTown	Fremont
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94538
	dei	City Area Code CityAreaCode	(510)
	dei	Local Phone Number LocalPhoneNumber	545-1045
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	ASNS
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6016326	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2412000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	620000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	790000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	6541000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5912000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	61000	usd
CY2024Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	592000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	592000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	160000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3330000	usd
CY2024Q2	asns	Restricted Bank Deposits Noncurrent RestrictedBankDepositsNoncurrent	89000	usd
CY2023Q4	asns	Restricted Bank Deposits Noncurrent RestrictedBankDepositsNoncurrent	94000	usd
CY2024Q2	asns	Severance Pay Fund Noncurrent SeverancePayFundNoncurrent	235000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	608000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	918000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	78000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1816000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	5311000	usd
CY2024Q2	us-gaap	Assets Assets	8357000	usd
CY2023Q4	us-gaap	Assets Assets	11223000	usd
CY2024Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1045000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	460000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1335000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1421000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1769000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	206000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	389000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	782000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	737000	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1119000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1062000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	443000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	995000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1122000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6912000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	263000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	45000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	405000	usd
CY2024Q2	asns	Accrued Severance Noncurrent AccruedSeveranceNoncurrent	263000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	749000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3923000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	7220000	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	1565000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	197000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	168000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	168000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	690000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	664000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2158000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2526000	usd
CY2024Q2	asns	Allowance For Doubtful Debts Prepaid Expenses AllowanceForDoubtfulDebtsPrepaidExpenses	181000	usd
CY2023Q4	asns	Allowance For Doubtful Debts Prepaid Expenses AllowanceForDoubtfulDebtsPrepaidExpenses	144000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	491000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	340000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	6541000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5912000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	55000	usd
CY2024Q2	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	592000	usd
CY2023Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	592000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	160000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	3330000	usd
CY2024Q2	asns	Restricted Bank Deposits Noncurrent RestrictedBankDepositsNoncurrent	89000	usd
CY2023Q4	asns	Restricted Bank Deposits Noncurrent RestrictedBankDepositsNoncurrent	94000	usd
CY2024Q2	asns	Severance Pay Fund Noncurrent SeverancePayFundNoncurrent	235000	usd
CY2023Q4	asns	Severance Pay Fund Noncurrent SeverancePayFundNoncurrent	238000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	608000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	918000	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	77000	usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments	78000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	1816000	usd
CY2024Q2	us-gaap	Assets Assets	8357000	usd
CY2024Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1045000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	460000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1335000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1421000	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1769000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	206000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	782000	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1119000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1062000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	443000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	498000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	995000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1122000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6471000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6912000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	263000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	3154000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	45000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	71000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	405000	usd
CY2024Q2	asns	Accrued Severance Noncurrent AccruedSeveranceNoncurrent	263000	usd
CY2023Q4	asns	Accrued Severance Noncurrent AccruedSeveranceNoncurrent	270000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	27000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	23000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	749000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	3923000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	7220000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	10835000	usd
CY2024Q2	asns	Warrants To Placement Agent WarrantsToPlacementAgent	201000	usd
CY2023Q4	asns	Warrants To Placement Agent WarrantsToPlacementAgent	159000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5017322	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5017322	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3007745	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3007745	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42687000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39916000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41752000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39688000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8357000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11223000	usd
	us-gaap	Revenues Revenues	4157000	usd
	us-gaap	Revenues Revenues	3744000	usd
CY2024Q2	us-gaap	Revenues Revenues	3431000	usd
CY2023Q2	us-gaap	Revenues Revenues	1896000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2424000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	1488000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1264000	usd
	us-gaap	Gross Profit GrossProfit	1320000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	1943000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	632000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1250000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	603000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	669000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1274000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1641000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	647000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	712000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1607000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1834000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	790000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	969000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	163000	usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	163000	usd
	us-gaap	Operating Expenses OperatingExpenses	3968000	usd
	us-gaap	Operating Expenses OperatingExpenses	4901000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1877000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2350000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1805000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3581000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	66000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1718000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	344000	usd
CY2024Q2	asns	Warrants To Placement Agent WarrantsToPlacementAgent	201000	usd
CY2023Q4	asns	Warrants To Placement Agent WarrantsToPlacementAgent	159000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5017322	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5017322	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42687000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39916000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41752000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39688000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	229000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8357000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11223000	usd
	us-gaap	Revenues Revenues	4157000	usd
	us-gaap	Revenues Revenues	3744000	usd
CY2024Q2	us-gaap	Revenues Revenues	3431000	usd
CY2023Q2	us-gaap	Revenues Revenues	1896000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1994000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2424000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	1488000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1264000	usd
	us-gaap	Gross Profit GrossProfit	2163000	usd
	us-gaap	Gross Profit GrossProfit	1320000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	1943000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	632000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1250000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1426000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	603000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1274000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1641000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	647000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	712000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1607000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1834000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	790000	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	163000	usd
CY2024Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	163000	usd
	us-gaap	Operating Expenses OperatingExpenses	3968000	usd
	us-gaap	Operating Expenses OperatingExpenses	4901000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	1877000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2350000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1805000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-3581000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	66000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1718000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	351000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	137000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	171000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	85000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	444000	usd
CY2024Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	351000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	137000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	171000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	85000	usd
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	444000	usd
CY2024Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	296000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2064000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3488000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1593000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.72
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4000994	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2033747	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4257674	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2333381	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3265000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	192000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1356000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	229000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	179000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2560000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1415000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	97000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1593000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1285000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1668000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	90000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2560000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
	us-gaap	Depreciation Depreciation	8000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-396000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	223000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	25000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
	asns	Exchange Rate Difference ExchangeRateDifference	79000	usd
	asns	Exchange Rate Difference ExchangeRateDifference	226000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	179000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	192000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	64000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1275000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-1000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-24000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-342000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	296000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2064000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3488000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1593000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2033747	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4257674	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2333381	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3265000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	192000	usd
	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	50000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1356000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1285000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	229000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	179000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2560000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1415000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	97000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1356000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	10000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1593000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1285000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1668000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	90000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	32000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2560000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	936000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
	us-gaap	Depreciation Depreciation	8000	usd
	us-gaap	Depreciation Depreciation	13000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-396000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	223000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	25000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
	asns	Exchange Rate Difference ExchangeRateDifference	79000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	192000	usd
	us-gaap	Interest Expense InterestExpense	-41000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-4000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	64000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1275000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-1000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	726000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	150000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-208000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-347000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	137000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-209000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	726000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	150000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-208000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-347000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	137000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-209000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-155000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	14000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-36000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-17000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2343000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939000	usd
	asns	Proceedsfrom Short Term Deposits ProceedsfromShortTermDeposits	198000	usd
	asns	Proceedsfrom Short Term Deposits ProceedsfromShortTermDeposits	810000	usd
	asns	Paymentto Short Term Restricted Bank Deposits PaymenttoShortTermRestrictedBankDeposits	125000	usd
	asns	Payments For Proceeds From Long Term Deposit PaymentsForProceedsFromLongTermDeposit	5000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	197000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	677000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	usd
	asns	Proceeds From Warrant Inducement Agreement ProceedsFromWarrantInducementAgreement	2999000	usd
	asns	Underwriting Discounts And Commissions And Other Offering Costs UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts	397000	usd
	asns	Underwriting Discounts And Commissions And Other Offering Costs UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts	291000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1045000	usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-3483000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	193000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	389000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2780000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2153000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	508000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5515000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4279000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3362000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4787000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2412000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2573000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	160000	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	2214000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3362000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4787000	usd
	us-gaap	Interest Paid Net InterestPaidNet	326000	usd
	us-gaap	Interest Paid Net InterestPaidNet	351000	usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants	104000	usd
	asns	Issuance Costs Of The Warrant Inducement Agreement IssuanceCostsOfTheWarrantInducementAgreement	1493000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2343000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41752000	usd
CY2024Q2	us-gaap	Cash Cash	3202000	usd
CY2024Q2	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	249000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-155000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	14000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-36000	usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-17000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2343000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939000	usd
	asns	Proceedsfrom Short Term Deposits ProceedsfromShortTermDeposits	198000	usd
	asns	Proceedsfrom Short Term Deposits ProceedsfromShortTermDeposits	810000	usd
	asns	Paymentto Short Term Restricted Bank Deposits PaymenttoShortTermRestrictedBankDeposits	125000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	197000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	677000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	32000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3500000	usd
	asns	Proceeds From Warrant Inducement Agreement ProceedsFromWarrantInducementAgreement	2999000	usd
	asns	Underwriting Discounts And Commissions And Other Offering Costs UnderwritingDiscountsAndCommissionsAndOtherOfferingCosts	397000	usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1045000	usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt	-3483000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	193000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	389000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2780000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-10000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2153000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	508000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5515000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4279000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4787000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2412000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2573000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent	790000	usd
CY2024Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	160000	usd
CY2023Q2	us-gaap	Restricted Cash Equivalents Noncurrent RestrictedCashEquivalentsNoncurrent	2214000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3362000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4787000	usd
	us-gaap	Interest Paid Net InterestPaidNet	326000	usd
	us-gaap	Interest Paid Net InterestPaidNet	351000	usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants	104000	usd
	asns	Issuance Costs Of The Warrant Inducement Agreement IssuanceCostsOfTheWarrantInducementAgreement	1493000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2939000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-41752000	usd
CY2024Q2	us-gaap	Cash Cash	3202000	usd
CY2024Q2	us-gaap	Restricted Cash And Investments RestrictedCashAndInvestments	249000	usd
	us-gaap	Other Income OtherIncome	163	usd
	us-gaap	Other Income OtherIncome	163	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Use of estimates in preparation of financial statements</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and cash equivalents, trade receivables and other current assets. Cash and cash equivalents and restricted cash and cash equivalents are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company has customers balances representing 10% or more of Trade receivables as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer A represented </span><span style="font-size: 10pt">15</span><span style="font-family: Times New Roman, Times, Serif">% and 30% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer B represented </span><span style="font-size: 10pt">14</span><span style="font-family: Times New Roman, Times, Serif">% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: justify">Customer C represented 0% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4)</span></td><td style="text-align: justify">Customer D represented 11% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt"><span style="font-size: 10pt">5)</span></td><td style="text-align: justify">Customer E represented 10% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>b.</b></td><td style="text-align: justify"><b>Use of estimates in preparation of financial statements</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, fair values of financial instruments, inventory write-offs, as well as in estimates used in applying the revenue recognition policy. The Company’s management believes that the estimates, judgments, and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the unaudited condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><b>d.</b></td><td style="text-align: justify"><b>Concentration of risk</b></td> </tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and cash equivalents, trade receivables and other current assets. Cash and cash equivalents and restricted cash and cash equivalents are placed with banks and financial institutions in the United States and Israel.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, present minimal credit risk with respect to those investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company’s trade receivables are derived primarily from telecommunication operators, the Company’s reseller customers and enterprises located mainly in the United States, Europe, and Asia.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Credit risk with respect to trade receivables exists to the full extent of the amounts presented in the consolidated financial statements. Management makes judgments as to its ability to collect outstanding accounts receivable and provides allowances for the applicable portion of accounts receivable when collection becomes doubtful.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">Management provides allowances based upon a specific review of all significant outstanding invoices, analysis of its historical collection experience, and current economic trends. If the historical data used to calculate the allowance for credit losses does not reflect the Company’s future ability to collect outstanding accounts receivable, additional provisions for credit losses may be needed, and the future results of operations could be materially affected.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company has customers balances representing 10% or more of Trade receivables as follows:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer A represented </span><span style="font-size: 10pt">15</span><span style="font-family: Times New Roman, Times, Serif">% and 30% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Customer B represented </span><span style="font-size: 10pt">14</span><span style="font-family: Times New Roman, Times, Serif">% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">3)</span></td><td style="text-align: justify">Customer C represented 0% and 11% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 1in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">4)</span></td><td style="text-align: justify">Customer D represented 11% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 70.9pt"></td><td style="width: 18pt"><span style="font-size: 10pt">5)</span></td><td style="text-align: justify">Customer E represented 10% and 0% of the Company Trade receivables balance as of June 30, 2024, and December 31, 2023, respectively.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify">The Company does not see any credit risk regarding the major trade receivable balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1132000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	757000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1769000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2158000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2526000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	25000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	25	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	90	usd
CY2024Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2000	usd
CY2020Q4	us-gaap	Loans Payable LoansPayable	20000000	ils
CY2020Q4	us-gaap	Loans Payable LoansPayable	6000000	usd
CY2020Q4	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	3000000	usd
CY2021Q1	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	2000000	usd
CY2024Q2	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.096	pure
CY2021Q4	us-gaap	Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation	1000000	usd
CY2021Q4	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.096	pure
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	1800000	usd
CY2022Q4	us-gaap	Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned	2000000	usd
CY2023Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2000000	usd
CY2024Q2	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	10900000	ils
CY2024Q2	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2933000	usd
CY2024Q1	us-gaap	Long Term Debt Percentage Bearing Fixed Interest Rate LongTermDebtPercentageBearingFixedInterestRate	0.096	pure
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	150000	usd
	us-gaap	Long Term Debt Average Amount Outstanding LongTermDebtAverageAmountOutstanding	1160000	ils
	us-gaap	Long Term Debt Average Amount Outstanding LongTermDebtAverageAmountOutstanding	308000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.015	pure
CY2024Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1045000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	757000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1026000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1769000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	2158000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	2526000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	25000	usd
	us-gaap	Inventory Write Down InventoryWriteDown	97000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	25	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	90	usd
CY2024Q2	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2000	usd
CY2020Q4	us-gaap	Loans Payable LoansPayable	20000000	ils
CY2020Q4	us-gaap	Loans Payable LoansPayable	6000000	usd
CY2020Q4	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	3000000	usd
CY2021Q1	us-gaap	Financing Receivable Loan In Process FinancingReceivableLoanInProcess	2000000	usd
CY2024Q2	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.096	pure
CY2021Q4	us-gaap	Investment Company Increase From Payment By Affiliate And Gain Loss From Investment In Violation InvestmentCompanyIncreaseFromPaymentByAffiliateAndGainLossFromInvestmentInViolation	1000000	usd
CY2021Q4	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.096	pure
	us-gaap	Warrant Down Round Feature Increase Decrease In Equity Amount1 WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1	1800000	usd
CY2022Q4	us-gaap	Carrying Value Of Securities Sold Under Repurchase Agreements And Deposits Received For Securities Loaned CarryingValueOfSecuritiesSoldUnderRepurchaseAgreementsAndDepositsReceivedForSecuritiesLoaned	2000000	usd
CY2023Q4	us-gaap	Long Term Notes And Loans LongTermNotesAndLoans	2000000	usd
CY2024Q1	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2000000	ils
CY2024Q1	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	550000	usd
CY2024Q2	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	10900000	ils
CY2024Q2	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	2933000	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	150000	usd
	us-gaap	Long Term Debt Average Amount Outstanding LongTermDebtAverageAmountOutstanding	308000	usd
CY2024Q1	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.015	pure
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.30	pure
CY2024Q2	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	1045000	usd
	asns	Royalties Paid Percentage RoyaltiesPaidPercentage	1	pure
CY2024Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	14300000	usd
CY2024Q2	us-gaap	Interest Receivable InterestReceivable	15825000	usd
	asns	Repaid Amount RepaidAmount	10275000	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	1119000	usd
CY2023	us-gaap	Payments For Royalties PaymentsForRoyalties	1062000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	190000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	asns	Prefunded Warrants To Purchase Common Stock PrefundedWarrantsToPurchaseCommonStock	754670	shares
CY2023Q2	asns	Prefunded Warrants PrefundedWarrants	754670	shares
CY2023Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q2	asns	Payments To Underwriter PaymentsToUnderwriter	291000	usd
CY2023Q2	asns	Warrant Exercise Price Percentage WarrantExercisePricePercentage	1.25	pure
CY2023Q4	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	1500000	usd
CY2023Q4	asns	Prefunded Warrants To Purchase Common Stock PrefundedWarrantsToPurchaseCommonStock	970187	shares
CY2023Q4	asns	Prefunded Warrants PrefundedWarrants	970187	shares
CY2023Q4	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0001
	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	970187	shares
	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.097
CY2023Q4	asns	Payments To Underwriter PaymentsToUnderwriter	129000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	88983	shares
CY2023Q4	asns	Offering Share Price OfferingSharePrice	1.475
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.
	asns	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables	P5Y6M
	asns	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining	P2Y
	asns	Existing Warrants Reduced Exercise Price ExistingWarrantsReducedExercisePrice	-3437.5000	usd
CY2024Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1890	usd
	asns	Royalties Paid Percentage RoyaltiesPaidPercentage	1	pure
CY2024Q2	us-gaap	Billed Contract Receivables BilledContractReceivables	14300000	usd
CY2024Q2	us-gaap	Interest Receivable InterestReceivable	15825000	usd
	asns	Repaid Amount RepaidAmount	10275000	usd
	us-gaap	Payments For Royalties PaymentsForRoyalties	1119000	usd
CY2023	us-gaap	Payments For Royalties PaymentsForRoyalties	1062000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	190000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	asns	Prefunded Warrants To Purchase Common Stock PrefundedWarrantsToPurchaseCommonStock	754670	shares
CY2023Q2	asns	Prefunded Warrants PrefundedWarrants	754670	shares
CY2023Q2	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	0.0001
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	754670	shares
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q3	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0755
CY2023Q2	asns	Payments To Underwriter PaymentsToUnderwriter	291000	usd
CY2023Q2	asns	Warrant Exercise Price Percentage WarrantExercisePricePercentage	1.25	pure
CY2023Q4	us-gaap	Proceeds From Payments For Long Term Loans For Related Parties ProceedsFromPaymentsForLongTermLoansForRelatedParties	1500000	usd
CY2023Q4	asns	Prefunded Warrants To Purchase Common Stock PrefundedWarrantsToPurchaseCommonStock	970187	shares
CY2023Q4	asns	Prefunded Warrants PrefundedWarrants	970187	shares
CY2023Q4	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.0001
	asns	Exercise Of Prefunded Warrant ExerciseOfPrefundedWarrant	970187	shares
	asns	Exercise Price Of Prefunded Warrant ExercisePriceOfPrefundedWarrant	0.097
CY2023Q4	asns	Payments To Underwriter PaymentsToUnderwriter	129000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	88983	shares
CY2023Q4	asns	Offering Share Price OfferingSharePrice	1.475
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	230000	usd
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	a 1:1 exchange ratio. As further consideration, the Holder agrees to pay $0.125 cents per newly issued warrant outlined above for a total of $249.
	asns	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisables ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisables	P5Y6M
	asns	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable Remaining ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisableRemaining	P2Y
	asns	Existing Warrants Reduced Exercise Price ExistingWarrantsReducedExercisePrice	-3437.5000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	87764	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.63
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M9D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21225	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1362	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.73
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	65102	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.39
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	58818	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M12D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65102	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	93708	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	4.39
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	4.81
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3159451000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1800665000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3998957000	usd
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	841543	shares
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	238979	shares
CY2024Q2	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	258717	shares
	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	5896000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4000994	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2033747	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.72
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.63
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M9D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	21225	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.37
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.73
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.39
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y7M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	58818	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.11
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y2M12D
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	65102	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	93708	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	4.39
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased	4.81
	us-gaap	Net Income Loss NetIncomeLoss	-2064000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-78000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1800665000	usd
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	841543	shares
	asns	Pre Funded Warrants To Purchase Common Shares PreFundedWarrantsToPurchaseCommonShares	238979	shares
	asns	Repurchase Of Common Stock RepurchaseOfCommonStock	5896000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4000994	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2033747	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4257674	shares
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.72
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	asns	Revenue Revenue	4158000	usd
	asns	Revenue Revenue	3744000	usd
CY2024Q2	asns	Revenue Revenue	3431000	usd
CY2023Q2	asns	Revenue Revenue	1896000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	460000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	648000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	364000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	544000	usd
	asns	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	155000	usd
CY2023	asns	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	356000	usd
CY2024Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	251000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	460000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	251000	usd
CY2024Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	69977	shares
	asns	Existing Warrants Being Exercised ExistingWarrantsBeingExercised	0.07	pure
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	2.5
	asns	Exercise Price Percentage ExercisePricePercentage	1.25	pure
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
	asns	Revenue Revenue	4158000	usd
	asns	Revenue Revenue	3744000	usd
CY2024Q2	asns	Revenue Revenue	3431000	usd
CY2023Q2	asns	Revenue Revenue	1896000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	460000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	648000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	364000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	544000	usd
	asns	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	155000	usd
CY2023	asns	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	356000	usd
CY2023Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	460000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	251000	usd
CY2024Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	69977	shares
	asns	Existing Warrants Being Exercised ExistingWarrantsBeingExercised	0.07	pure
	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	2.5
	asns	Exercise Price Percentage ExercisePricePercentage	1.25	pure
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	asns	Exercise Of Pre Funded Warrants Into Common Stock. ExerciseOfPreFundedWarrantsIntoCommonStock.		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4257674	shares
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	asns	Exercise Of Pre Funded Warrants Into Common Stock. ExerciseOfPreFundedWarrantsIntoCommonStock.		usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
	asns	Paymentto Short Term Restricted Bank Deposits PaymenttoShortTermRestrictedBankDeposits		usd
	asns	Payments For Proceeds From Long Term Deposit PaymentsForProceedsFromLongTermDeposit		usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
	asns	Proceeds From Warrant Inducement Agreement ProceedsFromWarrantInducementAgreement		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt		usd
CY2023Q2	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent		usd
	asns	Issuance Costs Of The Warrant Inducement Agreement IssuanceCostsOfTheWarrantInducementAgreement		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	asns	Repurchase Of Common Stock RepurchaseOfCommonStock		usd
CY2024Q2	asns	Repurchase Of Common Stock RepurchaseOfCommonStock		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2033747	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4000994	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4257674	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.72
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001141284
	us-gaap	Interest Expense InterestExpense		usd
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities		usd
	asns	Paymentto Short Term Restricted Bank Deposits PaymenttoShortTermRestrictedBankDeposits		usd
	asns	Payments For Proceeds From Long Term Deposit PaymentsForProceedsFromLongTermDeposit		usd
	asns	Proceeds From Warrant Inducement Agreement ProceedsFromWarrantInducementAgreement		usd
	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
	us-gaap	Proceeds From Repayments Of Other Long Term Debt ProceedsFromRepaymentsOfOtherLongTermDebt		usd
CY2023Q2	us-gaap	Restricted Cash Equivalents Current RestrictedCashEquivalentsCurrent		usd
	asns	Issuance Costs Of Common Stock Prefunded Warrants And Warrants IssuanceCostsOfCommonStockPrefundedWarrantsAndWarrants		usd
	asns	Issuance Costs Of The Warrant Inducement Agreement IssuanceCostsOfTheWarrantInducementAgreement		usd
	us-gaap	Net Income Loss NetIncomeLoss	-3488000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q2	asns	Repurchase Of Common Stock RepurchaseOfCommonStock		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2033747	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4257674	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001141284

Files In Submission

Name	View Source	Status
asns-20240630_cal.xml	Edgar Link	unprocessable
0001213900-24-069173-index-headers.html	Edgar Link	pending
0001213900-24-069173-index.html	Edgar Link	pending
0001213900-24-069173.txt	Edgar Link	pending
0001213900-24-069173-xbrl.zip	Edgar Link	pending
asns-20240630.xsd	Edgar Link	pending
ea0211159-10q_actelisnet.htm	Edgar Link	pending
ea021115901ex31-1_actelisnet.htm	Edgar Link	pending
ea021115901ex31-2_actelisnet.htm	Edgar Link	pending
ea021115901ex32-1_actelisnet.htm	Edgar Link	pending
ea021115901ex32-2_actelisnet.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
asns-20240630_def.xml	Edgar Link	unprocessable
asns-20240630_lab.xml	Edgar Link	unprocessable
asns-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ea0211159-10q_actelisnet_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASNS
ACTELIS NETWORKS INC Stock $asns

2024 Q3 Form 10-Q Financial Statement

#000121390024069173 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS ACTELIS NETWORKS INC Stock $asns

2024 Q3 Form 10-Q Financial Statement

#000121390024069173 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASNS
ACTELIS NETWORKS INC Stock $asns